Market Overview

Edison issues ADR outlook on Immutep (IMM)

Share:

LONDON, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immutep has reported encouraging progress from its in-house and partnered programs over the past few months. Interim data from the TACTI-mel combo study included a 61% response rate from the start of the Keytruda monotherapy screening period among subjects who went on to receive eftilagimod alpha (efti or IMP321) combo therapy. Partners GSK and Novartis are progressing their in-licensed LAG-3 programs into Phase II or proof of concept studies, which increases the likelihood that these programs will return significant value to Immutep. Our valuation has increased to $387m or $12.80/ADR (from $333m or $10.41/ADR).

Our valuation increases to $387m (from $333m). We have increased the probability for the programs partnered with Novartis and GSK, and have increased the forecast uptake of efti in lung cancer. Our valuation is equal to $12.80 per ADR on an undiluted basis (vs $10.41) or $9.08 after accounting for dilution from options, warrants and convertible notes (vs $7.61).

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Dr Dennis Hulme, +61 (0)2 8249 8345
Maxim Jacobs, +1 646 653 7027
healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 
LinkedIn  https://www.linkedin.com/company/edison-investment-research
Twitter     www.twitter.com/Edison_Inv_Res
YouTube   www.youtube.com/edisonitv

edison logo.png

View Comments and Join the Discussion!